FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment – PR Newswire (press release)
|
FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment
PR Newswire (press release) The therapy, axicabtagene ciloleucel (Yescarta ™), is the second of this new method of treatment, known as CAR (chimeric antigen receptor) T–cell immunotherapy, to receive FDA approval for blood cancer patients in the past six weeks, and the first to … |
